Mainstream

ADC Therapeutics targets $600M–$1B peak revenue potential for ZYNLONTA amid strategic refocus and cost cuts

ADC Therapeutics targets $600M–$1B peak revenue potential for ZYNLONTA amid strategic refocus and cost cuts

Post ContentadctRead More

You might also be interested in reading HBAR Shares Drop 4% as Institutional Selling Intensifies.

August 12, 2025
In Mainstream